Pemetinib/Pemetinib is from which company?

Pemigatinib is an oral targeted tumor treatment drug developed by the American pharmaceutical company Nash (Incyte Corporation). Nash Corporation was founded in 1991. It is a biopharmaceutical company that mainly develops and commercializes innovative pharmaceutical products, focusing on the fields of tumors, inflammation and autoimmune diseases.

Incyte has rich R&D experience and excellent scientific research strength in the field of oncology. Pemetinib, as an important drug developed by it, is widely used in the treatment of cholangiocarcinoma (CCA). Cholangiocarcinoma is a rare but highly aggressive and malignant cancer with relatively low survival rates. As a targeted therapeutic drug, pemetinib inhibits the FGFR (fibroblast growth factor receptor) signaling pathway and intervenes in the abnormal molecular changes in this pathological process, thereby inhibiting tumor growth and spread.

Incyte Company adheres to a rigorous scientific attitude and innovative research methods during the research and development process of pemetinib. Through a large number of clinical trials and preliminary studies, Nash Company has verified the safety and effectiveness of pemetinib and achieved remarkable results. The drug has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed or refractory cholangiocarcinoma with FGFR translocations or rearrangements. However, pemetinib has not yet been included in the scope of medical insurance in China, and patients need to purchase it at their own expense.

As a biopharmaceutical company with innovation as its core, Incyte is committed to promoting the advancement of medical technology and providing patients with better treatment options. Pemetinib, as an important drug developed by it, brings new treatment hope to patients with cholangiocarcinoma.